Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanja Fehm

Showing results (251-260 of 371) with videos related to

Pageof 38
Sort By:
Geburtshilfe Und Frauenheilkunde|April 6, 2023
Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Determining the axillary nodal status with four current imaging modalities including <sup>18</sup>F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standardJanna Morawitz, Nils-Martin Bruckmann, Frederic Dietzel, et al.
Clinical Chemistry|October 1, 2014
Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancerRui P L Neves, Katharina Raba, Oliver Schmidt, et al.
Breast Care (Basel, Switzerland)|November 1, 2021
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMetCornelia Kolberg-Liedtke, Rachel Wuerstlein, Oleg Gluz, et al.
The Lancet. Oncology|May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trialTanja Fehm, Francesco Cottone, Kyle Dunton, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 16, 2015
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT StudyChristina Fotopoulou, Jalid Sehouli, Nina Ewald-Riegler, et al.
International Journal of Cancer|June 2, 2025
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.
Journal of the National Cancer Institute|May 17, 2014
Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.
Acta Neuropathologica Communications|May 3, 2025
Identification and characterization of tertiary lymphoid structures in brain metastasesSadaf S Mughal, Yvonne Reiss, Jörg Felsberg, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2026
Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025Beyhan Ataseven, Marco Battista, Matthias W Beckmann, et al.
Pageof 38

Showing results (251-260 of 371) with videos related to

Sort By:
Pageof 38
Geburtshilfe Und Frauenheilkunde|April 6, 2023
Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Determining the axillary nodal status with four current imaging modalities including <sup>18</sup>F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standardJanna Morawitz, Nils-Martin Bruckmann, Frederic Dietzel, et al.
Clinical Chemistry|October 1, 2014
Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancerRui P L Neves, Katharina Raba, Oliver Schmidt, et al.
Breast Care (Basel, Switzerland)|November 1, 2021
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMetCornelia Kolberg-Liedtke, Rachel Wuerstlein, Oleg Gluz, et al.
The Lancet. Oncology|May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trialTanja Fehm, Francesco Cottone, Kyle Dunton, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 16, 2015
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT StudyChristina Fotopoulou, Jalid Sehouli, Nina Ewald-Riegler, et al.
International Journal of Cancer|June 2, 2025
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.
Journal of the National Cancer Institute|May 17, 2014
Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.
Acta Neuropathologica Communications|May 3, 2025
Identification and characterization of tertiary lymphoid structures in brain metastasesSadaf S Mughal, Yvonne Reiss, Jörg Felsberg, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2026
Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025Beyhan Ataseven, Marco Battista, Matthias W Beckmann, et al.
Pageof 38